دورية أكاديمية
Stage-related increase in PIM2 expression in mycosis fungoides.
| العنوان: | Stage-related increase in PIM2 expression in mycosis fungoides. |
|---|---|
| المؤلفون: | Nielsen MH; Department of Pathology, Copenhagen University Hospital - Zealand University Hospital Roskilde, Roskilde, Denmark., Nielsen PR; Department of Pathology, Copenhagen University Hospital - Zealand University Hospital Roskilde, Roskilde, Denmark.; Department of Immunology and Microbiology, LEO Foundation Skin Immunology Research Center, University of Copenhagen, Copenhagen, Denmark., Bzorek M; Department of Pathology, Copenhagen University Hospital - Zealand University Hospital Roskilde, Roskilde, Denmark., Eriksen JO; Department of Pathology, Copenhagen University Hospital - Zealand University Hospital Roskilde, Roskilde, Denmark., Wehkamp U; Department of Dermatology, University Hospital, Kiel, Schleswig-Holstein, Germany., Lindahl LM; Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark., Woetmann A; Department of Immunology and Microbiology, LEO Foundation Skin Immunology Research Center, University of Copenhagen, Copenhagen, Denmark., Ødum N; Department of Immunology and Microbiology, LEO Foundation Skin Immunology Research Center, University of Copenhagen, Copenhagen, Denmark., Litman T; Department of Immunology and Microbiology, LEO Foundation Skin Immunology Research Center, University of Copenhagen, Copenhagen, Denmark., Gjerdrum LMR; Department of Pathology, Copenhagen University Hospital - Zealand University Hospital Roskilde, Roskilde, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. |
| المصدر: | APMIS : acta pathologica, microbiologica, et immunologica Scandinavica [APMIS] 2024 Aug; Vol. 132 (8), pp. 564-570. Date of Electronic Publication: 2024 May 16. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Munksgaard Country of Publication: Denmark NLM ID: 8803400 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0463 (Electronic) Linking ISSN: 09034641 NLM ISO Abbreviation: APMIS Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Copenhagen : Munksgaard Original Publication: Copenhagen : Munksgaard, c1988- |
| مواضيع طبية MeSH: | Mycosis Fungoides*/genetics , Mycosis Fungoides*/pathology , Mycosis Fungoides*/metabolism , Proto-Oncogene Proteins*/genetics , Proto-Oncogene Proteins*/metabolism , Protein Serine-Threonine Kinases*/genetics , Protein Serine-Threonine Kinases*/metabolism, Humans ; Male ; Female ; Middle Aged ; Adult ; Aged ; Immunohistochemistry ; Skin Neoplasms/genetics ; Skin Neoplasms/pathology ; Aged, 80 and over ; Biopsy ; Skin/pathology ; Skin/metabolism ; Young Adult |
| مستخلص: | The oncogene PIM2 is upregulated in several malignancies but has never been investigated in mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma (CTCL). PIM2 is a well-known oncogene and is regulated by cell signaling pathways like the JAK/STAT- and NF-kB-pathway, key regulators in the pathogenesis of CTCL. The aim of this study was to examine the role of PIM2 in MF. PIM2 gene expression was measured in 81 formalin-fixed paraffin-embedded skin biopsies from patients with MF and 46 control biopsies from healthy skin (HS) and benign inflammatory skin disease (BID). Validation of PIM2 protein expression was performed on selected biopsies with immunohistochemical staining. We found a significant difference in gene expression levels between both early stage MF and HS (p < 0.0001), and BID (p < 0.0001). In addition, the PIM2 gene expression was higher in advanced-stage MF compared to early stage disease (p = 0.0001). No significant difference in gene expression levels was found between patients with and without disease progression. In conclusion, we found PIM2 expression is significantly increased in MF compared to controls, and in advanced-stage MF compared to early stage MF. These findings could potentially have diagnostic value in discriminating early stage MF from BID. (© 2024 Scandinavian Societies for Pathology, Medical Microbiology and Immunology.) |
| References: | Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO‐EORTC classification for primary cutaneous lymphomas. Blood. 2019;133:1703–1714. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of cancer (EORTC). Blood. 2007;110:1713–1722. Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, et al. European organisation for research and treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome—update 2017. Eur J Cancer. 2017;77:57–74. Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28:4730–4739. Scarisbrick JJ, Kim YH, Whittaker SJ, Wood GS, Vermeer MH, Prince HM, et al. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sezary syndrome: where are we now? Br J Dermatol. 2014;170:1226–1236. Molloy K, Jonak C, Woei AJF, Guenova E, Busschots AM, Bervoets A, et al. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sezary syndrome from the prospective cutaneous lymphoma international prognostic index (PROCLIPI) study. Br J Dermatol. 2020;182:770–779. Warfel NA, Kraft AS. PIM kinase (and Akt) biology and signaling in tumors. Pharmacol Ther. 2015;151:41–49. Mondello P, Cuzzocrea S, Mian M. Pim kinases in hematological malignancies: where are we now and where are we going? J Hematol Oncol. 2014;7:95. Yan B, Zemskova M, Holder S, Chin V, Kraft A, Koskinen PJ, et al. The PIM‐2 kinase phosphorylates BAD on serine 112 and reverses BAD‐induced cell death. J Biol Chem. 2003;278:45358–45367. Chen XP, Losman JA, Cowan S, Donahue E, Fay S, Vuong BQ, et al. Pim serine/threonine kinases regulate the stability of Socs‐1 protein. Proc Natl Acad Sci USA. 2002;99:2175–2180. Odum N. Deregulated signalling and inflammation in cutaneous T‐cell lymphoma. Br J Dermatol. 2020;182:16–17. Hammerman PS, Fox CJ, Cinalli RM, Xu A, Wagner JD, Lindsten T, et al. Lymphocyte transformation by Pim‐2 is dependent on nuclear factor‐kappaB activation. Cancer Res. 2004;64:8341–8348. Li J, Peet GW, Balzarano D, Li X, Massa P, Barton RW, et al. Novel NEMO/IkappaB kinase and NF‐kappa B target genes at the pre‐B to immature B cell transition. J Biol Chem. 2001;276:18579–18590. Cohen AM, Grinblat B, Bessler H, Kristt D, Kremer A, Schwartz A, et al. Increased expression of the hPim‐2 gene in human chronic lymphocytic leukemia and non‐Hodgkin lymphoma. Leuk Lymphoma. 2004;45:951–955. Kapelko‐Slowik K, Urbaniak‐Kujda D, Wolowiec D, Jazwiec B, Dybko J, Jakubaszko J, et al. Expression of PIM‐2 and NF‐kappaB genes is increased in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and is associated with complete remission rate and overall survival. Postepy Hig Med Dosw. 2013;67:553–559. Ren K, Gou X, Xiao M, Wang M, Liu C, Tang Z, et al. The over‐expression of Pim‐2 promote the tumorigenesis of prostatic carcinoma through phosphorylating eIF4B. Prostate. 2013;73:1462–1469. Nielsen PR, Eriksen JO, Wehkamp U, Lindahl LM, Gniadecki R, Fogh H, et al. Clinical and histological characteristics of mycosis Fungoides and Sezary syndrome: a retrospective, single‐centre study of 43 patients from eastern Denmark. Acta Derm Venereol. 2019;99:1231–1236. Nielsen PR, Eriksen JO, Sorensen MD, Wehkamp U, Lindahl LM, Bzorek M, et al. Role of B‐cells in mycosis Fungoides. Acta Derm Venereol. 2021;101:adv00413. Nielsen PR, Eriksen JO, Lindahl LM, Wehkamp U, Bzorek M, Andersen G, et al. Diagnostic two‐gene classifier in early‐stage mycosis Fungoides: a retrospective multicenter study. J Invest Dermatol. 2021;141:213–217. Fredholm S, Litvinov IV, Mongan NP, Schiele S, Willerslev‐Olsen A, Petersen DL, et al. The expression of IL‐21 is promoted by MEKK4 in malignant T cells and associated with increased progression risk in cutaneous T‐cell lymphoma. J Invest Dermatol. 2016;136:866–869. Litvinov IV, Netchiporouk E, Cordeiro B, Dore MA, Moreau L, Pehr K, et al. The use of transcriptional profiling to improve personalized diagnosis and Management of Cutaneous T‐cell lymphoma (CTCL). Clin Cancer Res. 2015;21:2820–2829. Litvinov IV, Jones DA, Sasseville D, Kupper TS. Transcriptional profiles predict disease outcome in patients with cutaneous T‐cell lymphoma. Clin Cancer Res. 2010;16:2106–2114. Zhang Q, Wang H, Kantekure K, Paterson JC, Liu X, Schaffer A, et al. Oncogenic tyrosine kinase NPM‐ALK induces expression of the growth‐promoting receptor ICOS. Blood. 2011;118:3062–3071. Amatore F, Ortonne N, Lopez M, Orlanducci F, Castellano R, Ingen‐Housz‐Oro S, et al. ICOS is widely expressed in cutaneous T‐cell lymphoma, and its targeting promotes potent killing of malignant cells. Blood Adv. 2020;4:5203–5214. Zhang Q, Wang HY, Wei F, Liu X, Paterson JC, Roy D, et al. Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7‐1) cell surface protein in a STAT5‐dependent manner. J Immunol. 2014;192:2913–2919. Yu X, Luo Y, Liu J, Liu Y, Sun Q. TOX acts an oncological role in mycosis fungoides. PLoS One. 2015;10:e0117479. Asati V, Mahapatra DK, Bharti SK. PIM kinase inhibitors: structural and pharmacological perspectives. Eur J Med Chem. 2019;172:95–108. Zhang X, Song M, Kundu JK, Lee MH, Liu ZZ. PIM kinase as an executional target in cancer. J Cancer Prev. 2018;23:109–116. Wozniak MB, Villuendas R, Bischoff JR, Aparicio CB, Martinez Leal JF, de La Cueva P, et al. Vorinostat interferes with the signaling transduction pathway of T‐cell receptor and synergizes with phosphoinositide‐3 kinase inhibitors in cutaneous T‐cell lymphoma. Haematologica. 2010;95:613–621. |
| معلومات مُعتمدة: | Aage Bang Foundation; NNF20OC0065549 Novo Nordisk Foundation; R269-A15742 Danish Cancer Society; Region Sjællands Sundhedsvidenskabelige Forskningsfond |
| فهرسة مساهمة: | Keywords: PIM2; cutaneous T‐cell lymphoma; mycosis fungoides |
| المشرفين على المادة: | 0 (PIM2 protein, human) 0 (Proto-Oncogene Proteins) EC 2.7.11.1 (Protein Serine-Threonine Kinases) |
| تواريخ الأحداث: | Date Created: 20240517 Date Completed: 20240710 Latest Revision: 20240710 |
| رمز التحديث: | 20240710 |
| DOI: | 10.1111/apm.13423 |
| PMID: | 38757234 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1600-0463 |
|---|---|
| DOI: | 10.1111/apm.13423 |